Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 17Stomach Neoplasms 5Rectal Neoplasms 2Colonic Neoplasms 2Advanced Colorectal Carcinoma 2Unresectable Metastatic Colorectal Cancer 1TAS 102 1Sarcoma 1Patients With Advanced Metastatic Colorectal Cancer 1Pancreatic Neoplasms 1Metastasis Colorectal Cancer 1Locally Advanced Rectal Cancer 1HER2-positive Gastric Cancer 1Fruquintinib 1Esophageal Squamous Cell Carcinoma 1Colorectal Adenocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Biliary Tract Adenocarcinoma 1Advanced Pancreatic Carcinoma 1

Interventions

Capecitabine 7Irinotecan 5spartalizumab 3Oxaliplatin 3Neoadjuvant Therapy 3Immune Checkpoint Inhibitors 2tislelizumab 1sintilimab 1nimotuzumab 1Radiotherapy 1Radiation 1HMPL-013 1Fluorouracil 1Combined Modality Therapy 1Chemoradiotherapy 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Locally Advanced Rectal Cancer × HMPL-013 × Clear all
NCT04989855 2021-08-04

Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score

Sun Yat-sen University

Phase 2 Unknown
48 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡